Post Profile






Alzheimer's treatment innovation pipeline is building

(Amplify Public Affairs) A new analysis of the Phase II Alzheimer's drug pipeline, conducted by ResearchersAgainstAlzheimer's, revealed 57 new Alzheimer's drugs. According to the analysis, nearly twice as many mechanisms of action are being tested in Phase II than in Phase III clinical trials. This diverse pipeline is important as it will give physicians, people with Alzheimer's and their loved ones new ways to combat the disease in the future.
read more

share

Related Posts


Merck's Alzheimer's Disease BACE Inhibitor Drug MK-8931 Begins Phase II/III Clinical Trial

Health : Medical News Today

Merck has just initiated a Phase II/III clinical trial of its Alzheimer's disease drug MK-8931. The trial will evaluate how effective the drug is versus a placebo among mild-to-moderate Alzheimer's disease patients. The MK-8931 is a...

Lilly To Launch New Alzheimer's Drug Phase 3 Trial

Health : Medical News Today

Eli Lilly have just announced plans to carry out a new large scale trial of their new drug solanezumab for treatment of mild Alzheimer's disease. The company decided not to submit a Biologics License Application (BLA) in the U.S bas...

Yeast Model Reveals Alzheimer's Drug Candidate and Its Mechanism of Action

Health : Newswise Medical News

Whitehead Institute scientists have used a yeast cell-based drug screen to identify a class of molecules that target the amyloid-? (A?) peptide involved in Alzheimer's disease (AD).

Diabetes drug enters clinical trial for Alzheimer's treatment

Health : Medical News Today

A drug commonly used for treating diabetes may reverse symptoms of late-stage Alzheimer's disease and is now in the process of entering a major clinical trial. Researchers from Lancaster University in the UK conducted a study reveal...

New Clinical Trial Will Test Cancer Drug as Alzheimer's Treatment

Health : Newswise Medical News

The Alzheimer's Drug Discovery Foundation (ADDF) announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tas...

Comments


Copyright © 2016 Regator, LLC